MedPath

Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy

Terminated
Conditions
Breast Cancer
Registration Number
NCT00542594
Lead Sponsor
AstraZeneca
Brief Summary

The purpose of this survey is to describe long-term tolerance as seen under current conditions of use for anastrozole.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
1840
Inclusion Criteria
  • woman treated with anastrozole as adjuvant therapy for hormone-dependant breast cancer in post-menopausal women with positive hormone-receptors
Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath